comparemela.com

Latest Breaking News On - லுட்விக் நிறுவனம் க்கு புற்றுநோய் ஆராய்ச்சி - Page 1 : comparemela.com

Oxford COVID vaccine technology has the potential to revolutionize cancer treatment

Scientists from the University of Oxford and the Ludwig Institute for Cancer Research are building on the success of the Oxford-AstraZeneca vaccine against SARS-CoV-2 to develop a vaccine to treat cancer.

Dr Tom Mikkelsen Recognized as a Worldwide Expert for Brain Cancer

Unexpected proteome plasticity in response to persistent temperature rise

Unexpected proteome plasticity in response to persistent temperature rise
eurekalert.org - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from eurekalert.org Daily Mail and Mail on Sunday newspapers.

Kojin Therapeutics Debuts to Solve Difficult Diseases Through Cell Behavior

Published: Jun 09, 2021 By Mark Terry Kojin Therapeutics launched with a $60 million Series A to initially focus on oncology and cell state biology. The round was led by Polaris Partners, Newpath Partners, and Cathay Health, affiliated to Cathay Capital. Participants included Leaps by Bayer, AbbVie, Eventide Asset Management, Alexandria, the Dana-Farber Cancer Institute’s Binney Street Capital, and several family offices. The approach came out of the laboratoryof Stuart Schreiber, Harvard University professor and co-founder of the Broad Institute. Co-founders of Kojin include Benjamin Cravatt, Stephanie Dougan and Vasanthi Viswanathan. The company’s technology is ferroptosis-based drug discovery, which is to say, iron-dependent cell death. Kojin says that difficult-to-treat diseases, which includes drug-resistant cancers, involve diseased cells that are sensitive to ferroptosis.

© 2024 Vimarsana

vimarsana © 2020. All Rights Reserved.